Search Results - Meir Schechter

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription

    α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription by Dana Davidi, Meir Schechter, Suaad Abd Elhadi, Adar Matatov, Lubov Nathanson, Ronit Sharon

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate

    α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate by Meir Schechter, Merav Atias, Suaad Abd Elhadi, Dana Davidi, Daniel Gitler, Ronit Sharon

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson’s Disease

    Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson’s Disease by Suaad Abd-Elhadi, Asaf Honig, Dganit Simhi-Haham, Meir Schechter, Eduard Linetsky, Tamir Ben‐Hur, Ronit Sharon

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes

    From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes by Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A. Leiter, Antonio Ceriello, Ralph A. DeFronzo, Itamar Raz

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease

    Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease by Cheli Melzer Cohen, Meir Schechter, Aliza Rozenberg, Ilan Yanuv, Dvora R. Sehtman‐Shachar, Alisa Fishkin, Doron Rosenzweig, Gabriel Chodick, Avraham Karasik, Ofri Mosenzon

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS by Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L. Neuen, Bruce Neal, Clare Arnott, Vlado Perkovic, Paul M. Ridker, Katherine R. Tuttle, Michael K. Hansen, Hiddo J.L. Heerspink

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty

    Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty by Priya Vart, Jawad H. Butt, Niels Jongs, Meir Schechter, Glenn M. Chertow, David C. Wheeler, Roberto Pecoits–Filho, Anna Maria Langkilde, Ricardo Correa‐Rotter, Peter Rossing, John J.V. McMurray, Hiddo J.L. Heerspink

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

    Dapagliflozin and Anemia in Patients with Chronic Kidney Disease by Akihiko Koshino, Meir Schechter, Glenn M. Chertow, Priya Vart, Niels Jongs, Robert D. Toto, Peter Rossing, Ricardo Correa‐Rotter, John J.V. McMurray, José Luis Górriz, Rey Isidto, Naoki Kashihara, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

    Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial by Meir Schechter, Stephen D. Wiviott, Itamar Raz, Erica L. Goodrich, Aliza Rozenberg, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Martin Fredriksson, Peter A. Johansson, Lawrence A. Leiter, Deepak L. Bhatt, Darren K. McGuire, John Wilding, Ingrid Gause‐Nilsson, Avivit Cahn, Anna Maria Langkilde, Marc S. Sabatine, Ofri Mosenzon

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

    The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 by Ofri Mosenzon, Stephen D. Wiviott, Hiddo J.L. Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Ingrid Gause‐Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A. Johansson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John Wilding, Marc S. Sabatine, Itamar Raz

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

    Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial by Ofri Mosenzon, Itamar Raz, Stephen D. Wiviott, Meir Schechter, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Sabina A. Murphy, Thomas A. Zelniker, Anna Maria Langkilde, Ingrid Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, John Wilding, Darren K. McGuire, Deepak L. Bhatt, Lawrence A. Leiter, Avivit Cahn, Jamie P. Dwyer, Hiddo J.L. Heerspink, Marc S. Sabatine

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: